Skip to main content
Marijo Bilusic, MD, Oncology, Miami, FL

MarijoBilusicMDPhD

Oncology Miami, FL

Genitourinary Oncology

Professor of Clinical Medicine Genitourinary Site Disease Group Leader

Dr. Bilusic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bilusic's full profile

Already have an account?

  • Office

    1120 NW 14th St Ste 610b
    Miami, FL 33136
    Phone+1 305-243-9779
    Fax+1 305-243-0424

Summary

  • Dr. Marijo Bilusic, MD, PhD, is a board-certified medical oncologist who treats genitourinary tumors (adrenal, kidney, prostate, bladder, and testis). His current research interests focus on tumor immunology and the development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, immune modulators or immune checkpoint inhibitors.
    Dr. Bilusic received his M.D. degree from the University of Zagreb School of Medicine in Croatia and completed his Ph.D. training at the University of Split School of Medicine in Croatia. In addition, he completed a postdoctoral research fellowship in physiological genomics at the Medical College of Wisconsin's Human and Molecular Genetics Center in Milwaukee, WI. He successfully completed a clinical fellowship in medical oncology and hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI), in Bethesda, MD.
    Dr. Bilusic served as an assistant professor Genitourinary medical oncology) at the Fox Chase Cancer Center/Temple Health from 2012 – 2016 and then joined the NCI Genitourinary Malignancy Branch in 2016 as an Associate Research Physician (equivalent to Associate Professor). During his time at the NCI, he also served as Associate Program Director, NIH Hematology Oncology Fellowship Program from July 2016 – July 2018, and then as Program Director from July 2018 – July 2021. In 2017 Dr. Bilusic received the National Institutes of Health (NIH) Director's Award as a member of NIH Hematology Oncology Fellowship Team for extraordinary resourcefulness and initiative. His passion for teaching and mentoring has earned multiple awards at NIH and NCI.
    In July 2021, Dr. Bilusic joined Sylvester Comprehensive Cancer Center / University of Miami Health System as GU Medical Oncology Team Lead. He is board-certified in medical oncology, hematology, and internal medicine.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Rutgers Health/Trinitas Regional Medical Center
    Rutgers Health/Trinitas Regional Medical CenterChief Residency, Internal Medicine, 2008 - 2009
  • Rutgers Health/Trinitas Regional Medical Center
    Rutgers Health/Trinitas Regional Medical CenterResidency, Internal Medicine, 2005 - 2008
  • University of Split School of Medicine
    University of Split School of MedicinePh.D., 2000 - 2005
  • University of Zagreb Faculty of Medicine
    University of Zagreb Faculty of MedicineClass of 1997

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - 2027
  • PA State Medical License
    PA State Medical License 2012 - 2022
  • NJ State Medical License
    NJ State Medical License 2008 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Educational Institution and Federal Laboratory Partnership award Federal Laboratory Consortium (FLC) Mid-Atlantic Region, 2018
  • Clinical Excellence Award CCR (Center for Cancer Research), 2017
  • NIH Director�s Award 2017
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial  
    Anari F, O�Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, R Alpaugh K, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, L..., European Urologu Oncology, 1/1/2018
  •  
    Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M, Schlom J, Urol Oncol., 1/1/2018
  • Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer  
    Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN, J Oncol Pract., 1/1/2016
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatec...
    Gulley JL, Sater HA, Marte J, Donahue RN, Rodriguez BW, Heery CR, Stern M, Thompson D, Cordes LM, Chun G, Karzai F, Bilusic M, Schlom J, Dahut WL, Madan RA, Pinto PA, ASCO Annual Meeting. J Clin Oncol, 1/1/2018
  • Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability
    Al Harthy M, Singh H, Karzai F, Arlen P, Theoret M, Marte J, Bilusic M, Couvillon A, Owens H, Hankin A, Cordes L, Rosner I, Strauss J, Figg WD, Schlom J, Dahut W, ..., ESMO Annual Meeting. Annals of Oncology, 1/1/2018
  • A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
    Karzai F, Madan RA, Owens H, Couvillon A, Hankin A, Williams M, Bilusic M, Cordes LM, Trepel JB, Killian K, Meltzer PS, Gulley JL, Lee J, Dahut WL, GU ASCO Annual Meeting. Journal of Clinical Oncology, 1/1/2018
  • Join now to see all

Lectures

  • Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development Course 
    Washington, DC - 1/18/2018
  • Medical Management of Prostate Cancer 
    Lafayette Hill, PA - 1/19/2014
  • Best of Journals: Prostate Cancer 
    San Francisco, CA - 1/31/2014
  • Join now to see all

Press Mentions

  • Bladder Cancer Awareness Month: 2020 Immunotherapy Research Update
    Bladder Cancer Awareness Month: 2020 Immunotherapy Research UpdateMay 23rd, 2020
  • Kidney Cancer Awareness Month: 2020 Immunotherapy Research Update
    Kidney Cancer Awareness Month: 2020 Immunotherapy Research UpdateMarch 12th, 2020
  • National Institutes of Health Clinical Center Hematology Oncology Fellowship
    National Institutes of Health Clinical Center Hematology Oncology FellowshipApril 30th, 2017
  • Join now to see all

Professional Memberships

Other Languages

  • Croatian